Triple-Negative Breast Cancer First In England As NICE Reverses Tecentriq Rejection
Executive Summary
Roche has resolved the issues raised by the health technology assessment body over what is the first immunotherapy approved for treating this aggressive and difficult-to-treat form of breast cancer.